Dr. Alex Welte, visiting research fellow at SACEMA, attended the XVI Conference on Retroviruses and Opportunistic Infections in February this year in Canada and presents you the highlights. South and Southern Africa were well represented. James McIntyre and Glenda Gray held the address on the openings day on responding to the HIV Epidemic in Soweto. Read More
Chigwedere P, Seage GR 3rd, Gruskin S, Lee TH. Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr. 2008;49(4):410-5.
The fifth forum of the European and Developing countries clinical trials partnership (EDCTP) will take place from 12 to 14 October 2009 in Arusha, Tanzania. The Forum’s theme reflects the global call for all partners and stakeholders to work together to rid the world the suffering of these diseases of poverty. Researchers involved in clinical Read More
It gives me great pleasure to introduce to you the first issue of a Quarterly Magazine produced by SACEMA – the DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis. It is our aim to provide regular updates, articles and reviews of developments in the world of quantitative epidemiology – with particular reference to the human health in the South African scene and to advances in the fight against the twin scourges of HIV and TB.
Recently the Lancet published the results of a randomized controlled trial which failed to show the effectiveness of the vaginal microbicide gel Carraguard to protect women from becoming HIV infected. This article extensively describes the study methods and results. Furthermore, it reports on ongoing trials on microbicides similair to Carraguard, and those on microbicides that contain antiretroviral drugs (new generation).
A significant contributing factor to the high incidence rates of tuberculosis (TB) in countries such as South Africa is the phenomenon of reinfection leading to further disease episodes. Researchers of SACEMA explored the relationship between incidence of TB and reinfection further by constructing a model that simulates the epidemiology of a TB endemic. This article describes the results of this analysis and recommendations based on these.
The Lancet recently reported that universal HIV testing and immediate antiretroviral therapy (ART) for everyone diagnosed with HIV in countries such as South Africa could reduce new infections by 95% within ten years. This article describes the benefits and objections (costs, human resources, side effects, drug resistance) to the idea of starting all HIV positives on ART in South Africa, including the way forward.